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Abstract
Background: Tuberculous pleural effusion (TPE) is a paucibacillary manifestation of tuberculosis, so isolation of
Mycobacterium tuberculosis is difficult, biomarkers being an alternative for diagnosis. Adenosine deaminase (ADA) is the
most cost-effective pleural fluid marker and is routinely used in high prevalence settings, whereas its value is questioned in
areas with low prevalence. The lymphocyte proportion (LP) is known to increase the specificity of ADA for this diagnosis. We
analyse the diagnostic usefulness of ADA alone and the combination of ADA $40 U/l (ADA40) and LP$50% (LP50) in three
different prevalence scenarios over 11 years in our area.
Materials and Methods: Biochemistry, cytology and microbiology studies from 472 consecutive pleural fluid samples were
retrospectively analyzed. ADA and differential cell count were determined in all samples. We established three different
prevalence periods, based on percentage of pleural effusion cases diagnosed as tuberculosis: 1998–2000 (31.3%), 2001–
2004 (11.8%), and 2005–2008 (7.4%). ROC curves, dispersion diagrams and pre/post-test probability graphs were produced.
TPE accounted for 73 episodes (mean prevalence: 15.5%). The sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) for ADA40 were 89%, 92.7%, 69.2% and 97.9%, respectively. For ADA40+LP50 the specificity
and PPV increased (98.3% and 90%) with hardly any decrease in the sensitivity or NPV (86.3% and 97.5%). No relevant
differences were observed between the three study periods.
Conclusions/Significance: ADA remains useful for the diagnosis of TPE even in low-to-intermediate prevalence scenarios
when combined with the lymphocyte proportion.
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Introduction
Tuberculous pleural effusion (TPE) is a common manifestation
of extrapulmonary tuberculosis, and is the leading cause of pleural
effusion in developing world regions, while it is much less common
in developed countries [1–3].
The diagnosis of TPE depends on the demonstration of tubercle
bacilli in pleural fluid, a pleural biopsy specimen or sputum, or the
demonstration of granulomas in the pleura [4]. Due to the paucity
of Mycobacterium tuberculosis in the pleural fluid, the performance of
a pleural biopsy has historically been considered the most reliable
method to confirm the diagnosis when tuberculous aetiology of a
pleural effusion is suspected. However, since pleural tissue
sampling is more difficult than simple thoracocentesis, pleural
fluid markers of TPE have been extensively evaluated as an
attractive alternative to pleural biopsy [5]. ADA is the most cost-
effective pleural fluid marker and is routinely employed as a
screening tool, in particular, in countries where tuberculosis is
endemic [1].
Theoretically, according to Bayes theorem, the predictive value
of a marker such as ADA depends not only on its sensitivity and
specificity, but also on the local prevalence of the disease: in a high
prevalence setting the positive predictive value (PPV) of elevated
ADA would increase, while in a low prevalence setting the PPV
would decline but the negative predictive value (NPV) would
remain high, so a low concentration of ADA might rule out TPE
[1,5]. On the other hand, the combination of ADA and the pleural
fluid lymphocyte proportion (LP) has come to be recognised as an
excellent approach for increasing the specificity of ADA test [6].
The aim of this research was to assess the accuracy of ADA
combined with pleural fluid LP for TPE in our area, in three
different prevalence settings over a total period of eleven years.
Methods
We retrospectively reviewed all consecutive patients with pleural
effusion who underwent a diagnostic thoracocentesis at Mendaro
Hospital (community hospital, which provides healthcare to Bajo
Deba Area - 80,000 inhabitants - in Basque Country, Spain) from
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38729January 1998 to December 2008. The ADA level and LP in
pleural fluid had been determined in all samples. We recorded
demographic and clinical data (body temperature on admission,
and presence of cough, chest pain and/or dyspnoea), and pleural
fluid data (total and differential cell count, protein, lactate
dehydrogenase-LDH, pH, glucose, ADA, cytology, aerobic and
anaerobic culture, Lowenstein-Jensen and MGIT-Bactec culture),
along with serum glucose, protein and LDH. Histopathological
and microbiological findings in pleural biopsy specimens, final
diagnosis and, in TPE cases, first and last day of treatment and the
combination of anti-tuberculosis drugs given were also recorded.
When more than one thoracocentesis was performed, the
statistical analysis was performed using only the data from the
first pleural fluid sample, although the outcomes of every sample
were recorded.
Regarding the diagnostic criteria, two subclasses of TPE were
identified: 1) confirmed pleural tuberculosis (CPTE): identification
of the bacillus in pleural fluid, sputum or pleural biopsy by stain or
by culture; or by the presence of granulomatous inammation on
pleural biopsy, and 2) probable pleural tuberculosis (PTPE):
clinical and radiological evidence for tuberculosis in the absence of
any other obvious cause associated with pleural effusion and
positive response to a complete course of anti-tuberculosis
treatment, confirmed through outpatient follow-up of at least
twelve months. Malignant effusion was diagnosed when malignant
cells were found in pleural fluid or pleural biopsy. Uncomplicated
parapneumonic effusion (UPE) referred to any exudative effusion
associated with bacterial pneumonia, lung abscess or bronchiec-
tasis which resolved with antibiotics alone, while patients with pH
,7.20 or glucose ,40 mg/dl or Gram’s stain or culture positive
were classed as having complicated parapneumonic effusion
(CPE), with empyema describing the presence of frank pus in
the pleural cavity [7]. Within the miscellaneous group of diagnoses
we included other types of pleural effusion with different
aetiologies and defined by well established clinical criteria.
Transudative effusions were defined following Light’s criteria
[8]. Finally, there was a last group for patients with pleural effusion
in whom an exact diagnosis had not been reached.
For the purposes of this study, following the approach of
previous authors, ‘‘prevalence’’ was used to refer to the number of
cases of a given type of pleural effusion divided by the total
number of pleural effusions studied, more appropriately named
‘‘pre-test probability’’ [1,5,9].
Pleural fluid ADA levels were determined by using an
automated ultraviolet kinetic assay (Roche Diagnostics, Mann-
heim, Germany). White blood cells were manually counted in a
Thoma chamber, and differential cell counts in pleural fluid were
performed after Wright’s staining by counting, whenever possible,
200 cells. The LP was calculated as the number of lymphocytes
divided by the total number of white cells.
Statistical analysis was performed using SPSS 18.0 statistical
software. Categorical variables were analyzed with the x
2 test and
continuous variables were compared using the Student’s t-test. In
addition, whenever parametric tests could not be used, Kruskal–
Wallis one-way analysis of variance was performed to compare
group means. Assessing the performance with the ROC curve, we
explored the usefulness of a single parameter relating the ADA
levels to the proportion of lymphocytes; specifically, we multiplied
the level of ADA by the LP, calling the resulting new variable
ADA?LP. Diagnostic accuracy, including 95% confidence inter-
vals, assessed using sensitivity, specificity, predictive values,
likelihood ratios and area under the ROC curve (AUC) in the
tuberculosis and non-tuberculosis sub-groups. ROC curves were
constructed to compare ADA with ADA?LP. Whenever appro-
priate, Pearson’s correlation coefficient was also calculated.
This research counts with the permission of the CEO of the
Mendaro Hospital and the approval of the Western Gipuzkoa
Research Commision for the development of the study.
Results
A total of 472 episodes of pleural effusion were analysed, with a
male:female ratio of 294:178 cases (62.3%:37.7%). Mean age was
66.2 years (SD of 20.25 years).
Overall, there were 73 cases of TPE (15.4%), 29 of CPE or
empyema (6.1%), 92 of UPE (19.5%), 105 of malignant effusion
(22.2%), 78 of miscellaneous exudates (16.5%), 61 of transudative
effusion (12.9%) and 34 of undiagnosed pleural effusion (7.2%).
Among the 73 episodes of TPE, 25 cases were confirmed to be
pleural tuberculosis (CTPE) (19 by positive culture and 6 by
presence of granulomas in pleural biopsy tissue) and the remaining
48 cases were probable pleural tuberculosis (PTPE), given the
clinical symptoms combined with biochemical and cytological
results from pleural fluid and response to a complete course of
treatment.
ADA activity was significantly higher in CTPE, PTPE and
CPE/empyema (Table 1). Specifically, using the Kruskal-Wallis
one-way analysis of variance, we found statistically significant
differences in mean ADA levels between the CTPE, PTPE and
CPE/empyema group and the other diagnostic entities: UPE,
malignant effusions, miscellaneous exudates, transudative and
undiagnosed effusions. Differences between tuberculosis (con-
firmed or probable) and CPE/empyema were not significant.
Nevertheless, CTPE and PTPE were easily distinguished from
CPE/empyema by the pleural fluid white cell count: mean LP in
TPE and CPE/empyema being 83.3% and 16%, respectively. In
Table 2 we report the number and percentage of positive results
obtained for the two diagnostic criteria used: an ADA level equal
to or greater than 40 U/l (ADA40) and a LP equal to or greater
than 50% (LP50), by type of pleural effusion. Although in six out of
the 25 patients with CTPE the ADA level was lower than 40 U/l
in the first pleural fluid sample, a subsequent thoracocentesis
yielded an ADA level higher than 40 U/l in four cases.
Over the whole period 1998–2008 (mean prevalence of 15.5%),
the sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) for ADA40 were 89.0%, 92.7%,
69.2% and 97.9% (Table 3). The addition of LP50 to ADA40
increased the specificity of the latter for the diagnosis of TPE to
98.3%, and its PPV to 90% (Table 4).
For ADA40+LP50, sensitivity, specificity, PPV and NPV
respectively were 87.8%, 100%, 100% and 94.7% for the first
period (1998–2000, prevalence: 31.3%); 83.3%, 99.3%, 93.8%
and 97.8% for the second period (2001–2004, prevalence: 11.8%);
and 85.7%, 96.6%, 66.7% and 98.8% for the third period (2004–
2008, prevalence: 7.4%).
For the whole period, the area under the ROC curve for ADA
levels was 0.939 (95% CI 0.908–0.969) versus 0.973 (95% CI:
0.949–0.997) for ADA?LP (Figure 1), with no statistically
significant differences between the three periods.
Notably, all malignant effusions developed in patients over 39
years old, and just four cases out of the 105 showed an ADA level
over 40 U/l, only two of them being found to be lymphocytic
(1.9%). TPE, in contrast, predominated in younger people and
even linear regression analysis showed that ADA activity decreased
slightly with the age of the patients affected by TPE (Pearson’s
correlation coefficient of 20.074). The ADA levels of 43 out of 73
patients with TPE were within the range of 40–70 U/l (Figure 2).
ADA Is Effective in Low Prevalence Settings
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38729We observed that six out of 75 (8%) cases of lymphocytic pleural
effusion had ADA.40 U/l and were of nontuberculous origin:
three empyemas and one UPE (all of them after admission and
drainage in another centres), along with two malignant effusions.
Further, amongst the cases of CPE/empyema, 20 out of 29 (69%)
were found to have an ADA level over 40 U/l, and all of them
(except for the three aforementioned cases) were neutrophilic.
Discussion
Due to the Bayesian interpretation of the well established
performance of ADA for the diagnosis of TPE, it has acquired
popularity as an excellent tool above all in areas of high incidence
of tuberculosis [10]. Nevertheless, the role of ADA in low-
intermediate prevalence settings remained uncertain, so our study
comes to demonstrate that combining ADA and LP in pleural fluid
the specificity and PPV of the former increase substantially,
especially in low-to-intermediate prevalence settings, making this
test a suitable diagnostic tool in such scenarios.
The definitive diagnosis of TPE depends on the demonstration
of Mycobacterium tuberculosis in pleural fluid, sputum or pleural
biopsy specimen, and can also be established with reasonable
certainty by demonstration of granuloma in the parietal pleura.
Microscopy of the pleural fluid for acid fast bacilli is positive in
fewer than 5% of cases and mycobacterial culture of pleural fluid
also has a low sensitivity of 35%. Closed pleural biopsy
demonstrates granulomas in approximately 80% of cases, and its
culture yields Mycobacterium tuberculosis in about 55%. Thoracosco-
py offers a near 100% positive diagnostic yield on histology and
76% positive on culture [1,11].
However, historically, since pleural biopsy is more invasive and
hazardous than thoracocentesis, alternative diagnostic approaches
have been extensively evaluated [2]. Unfortunately, only ADA
(sensitivity 92% and specificity 89%) [12] and IFN-c (sensitivity
89% and specificity 97%) [13] have become reliable for diagnosing
TPE. The long history of the successful use of the ADA test, its
simplicity, low cost, and quickly available results, make it the
preferred option [1,12,14]. Concern regarding the absence of
culture and sensitivity data when the diagnosis relies primarily on
the pleural fluid ADA value has been stated, and pleural biopsy is
thereby advised mostly in high mycobacterial resistance scenarios
[1]. On the other hand, the addition of a culture of the (closed)
pleural biopsy to that of the pleural fluid increases the overall
microbiological yield from 35% to 55%, and in some authors’
opinion this invasive practise may be not justified in order to
obtain such a diminished advantage [11].
Along with these biomarkers, nucleic acid amplification (NAA)
tests enable direct detection of Mycobacterium tuberculosis in clinical
specimens such as pleural fluid within hours of their collection, and
can also provide information regarding antimicrobial resistance
[1,11]. However, although commercial tests were found to have a
reasonably high specificity of 98% in a systematic review and
meta-analysis of 40 studies, they had a low and variable sensitivity
of 62% (95% CI: 43–77%) for diagnosing TPE [15]. Due to the
individual limitations of each test, even sophisticated and
expensive combinations of ADA, IFN-c and NAA tests have been
proposed [16].
Adenosine deaminase (ADA) is an essential enzyme in the
metabolism of purine nucleosides. There are two main isoenzymes
of ADA: ADA1 and ADA2. ADA 1 is ubiquitous, whereas ADA2
has been found only in monocytes and macrophages. Most of the
ADA in pleural tuberculosis is ADA2 [17]; although better than
total ADA for diagnosing pleural tuberculosis [18], the separation
of ADA into its isoenzymes is more expensive than the basic ADA
test, not readily available and its use is so far limited [1,5,11,19].
The most widely accepted cut-off level of ADA for the diagnosis of
TPE is 40 U/l [1,12,20], and an LP$50% is conventionally
accepted as a practical cut-off for lymphocytic effusion [21].
Moreover, ADA $70 U/l (when lymphocyte-to-neutrophil ratio is
$0.75) has also been proposed as virtual diagnosis of TPE [11].
High ADA levels in lymphocytic pleural effusions have also been
reported in rheumatoid arthritis, lymphoma, bronchoalveolar
carcinoma, mesothelioma, systemic lupus erythematosus, myco-
plasma and chlamydia pneumonia, psittacosis, paragonimiasis,
infectious mononucleosis, brucellosis, familial Mediterranean
fever, histoplasmosis and coccidioidomycosis [22]. However, apart
from tuberculosis, the main disease that causes an elevated ADA is
parapneumonic pleural effusion: one-third of cases of UPE and
two-thirds of those of CPE/empyema may have a high ADA level,
but both conditions are easily distinguished from TPE because
they develop neutrophilic effusions [1,5]. Moreover, several studies
with patients suffering from nontuberculous lymphocytic pleural
effusions have reported ADA levels over the diagnostic cut-off of
40 U/l in less than 3% of cases [23,24].
Table 1. ADA levels by type of pleural effusion in three tuberculosis pleural effusion prevalence periods (1998–2000, prevalence:
31.3%; 2001–2004, prevalence: 11.8%; and 2005–2008, prevalence: 7.4%).
Whole period 1998–2000 2001–2004 2005–2008
Mean
Standard
Deviation Mean
Standard
Deviation Mean
Standard
Deviation Mean
Standard
Deviation
CTPE 56.7 28.2 62.0 28.9 44.8 27.6 63.5 25.9
PTPE 64.2 16.2 63.1 16.0 66.2 21.6 65.3 11.3
CPE 64.8 42.3 71.6 62.1 71.8 42.2 59.2 37.4
UPE 21.8 10.5 14.2 7.7 21.0 9.6 25.0 10.6
Malignant 21.4 23.7 14.9 8.5 16.9 11.3 28.8 33.4
Miscellaneous 19.5 18.9 20.6 41.6 17.6 8.2 20.8 6.3
Transudative 9.7 5.3 6.2 2.7 8.6 4.0 13.0 5.6
Undiagnosed 19.0 8.5 12.6 3.8 18.5 8.2 25.2 7.6
Total 28.4 26.9 31.2 32.4 24.7 22.9 29.4 25.4
CTPE: confirmed pleural tuberculosis; PTPE: probable pleural tuberculosis; CPE: complicated parapneumonic effusion; UPE: uncomplicated parapneumonic effusion.
doi:10.1371/journal.pone.0038729.t001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38729Three major meta-analyses, based on 75 studies including a
total of 14,505 patients, have been performed over the last decade,
and these have demonstrated a uniformly high diagnostic
performance of pleural ADA for TPE [12,20,25]. One of the
major concerns regarding the sensitivity of ADA was its reliability
in immunocompromised patients; however, more recent studies
have demonstrated that ADA is a reliable marker of tuberculous
pleurisy in HIV-positive patients, even in those with a low CD4 T-
cell count [26,27]. On the other hand, ADA levels in pleural fluid
are also elevated in renal transplant recipients with tuberculous
pleurisy [5].
In 1998, Valde ´s et al. were the first to propose obviating pleural
biopsy for the diagnosis of tuberculous pleuritis in patients younger
than 35 years of age, in areas with an intermediate (say 25%) or
high prevalence of tuberculosis [28]. The limitation to young
patients was related to concern regarding the more common
development of malignant effusions in older patients [29] and this
approach was theoretically more suitable in intermediate-to-high
prevalence areas according to the Bayesian interpretation of the
predictive value of ADA.
To date, almost all the studies performed concerning the
diagnostic value of ADA for TPE were reported from interme-
diate-to-high prevalence areas, so acceptance of this test was not
universal and remained contentious in countries with lower
prevalence. Given this, it was considered desirable that further
studies be carried out in areas of low TPE prevalence in order to
confirm the suitability of this biomarker in these areas [30].
Within the Multicenter Project on Tuberculosis Research
performed in Spain from June 1996 to May 1997, the Bajo Deba
Area was found to have the highest incidence of tuberculosis in the
Basque Country (85 cases per 100,000 individuals) [31]. Subse-
quent implementation of a Tuberculosis Control Program by the
Basque Health Service led to sustained epidemiological improve-
ment. In the first period (1998–2000), with a 31% (intermediate-
to-high) TPE prevalence scenario, we obtained a sensitivity,
specificity, PPV and NPV of ADA40 for the diagnosis of TPE of
90.2%, 95.6%, 90.2% and 95.6%, close to values reported from
previous studies performed in similar clinical settings [9,10,32].
During the second and third periods the prevalence of TPE
declined to 11.8% and 7.8% respectively, closer to the epidemi-
ological scenario in most Western countries [1–3,12] (Figure 3). As
was expected, the PPV of ADA40 decreased to 68.2% and 41.9%
respectively, but the combination of ADA40 with LP50 increased
the specificity from 94.8% to 99.3% (second period) and from
89.7% to 96.6% (third period), and simultaneously the PPV rose
from 68.2% to 93.8% (second period) and from 41.9% to 66.7%
(third period).
In the intermediate-to-high prevalence period, both ADA40
and ADA40+LP50 gave very useful results. On the other hand,
the addition of LP50 had the benefit of improving the specificity
and PPV with respect to using ADA40 alone, especially when
the prevalence was lower: the lower the prevalence, the higher
this absolute increment (Tables 3 and 4). Accordingly, the
performance of ADA+LP was considerably better than ADA as
a single diagnostic variable, as can be seen in the post- vs. pre-
test probability plots. Specifically, for rates of pleural TPE
prevalence of 5%, 25% and 85% (estimated rates for low,
intermediate and high prevalence countries [12]), post-test
probabilities for an ADA40 were 41%, 81% and 99%
respectively; whereas for ADA40+ LP50 they were 78%, 95%
and 99% respectively (Figura 4).
Regarding the comparative study of TPE and malignant pleural
effusions (Figure 2), there are some interesting findings to
comment on: 1) all patients with malignant effusion in our series
were over 39 years of age, and almost all of them had an ADA
level ,40 U/l; and 2) TPE predominated in younger patients,
linear regression analysis demonstrating that ADA activity
decreased with age among the patients with TPE, as previously
reported by other authors [33]. Further, 43 out of 73 (59%)
patients diagnosed with TPE showed an ADA level in pleural fluid
of between 40 and 70 U/l. Finally, only two out of 105 patients
(1.9%) with malignant pleural effusion had an ADA level and LP
comparable to those theoretically attributable to TPE, so, as
reported by other authors [23,24], although always a concern, a
high ADA level in nontuberculous lymphocytic pleural effusions
(including malignant ones) is relatively uncommon.
Our study does have limitations: in particular, being retrospec-
tive, diagnoses based on clinical evidence were included, and
though this is not optimal it is considered acceptable [16]. We note
that the administration of empirical anti-tuberculosis treatment to
patients with lymphocytic exudates and a high ADA level in
pleural fluid when there is clinical suspicion of tuberculosis is a
common practice in intermediate-to-high burden settings like our
country [10]. Moreover, the universal determination of ADA level
in absolutely all pleural fluid samples taken, the absence of
significant differences between its mean level in the two diagnostic
groups (confirmed and probable pleural tuberculosis), and the
follow-up of all the patients diagnosed with TPE until complete
recovery under anti-tuberculosis treatment are positive features,
enhancing the validity of our study.
Table 3. Bayesian probabilities of test parameters used. ADA
$40 U/L.
ADA $40 U/L
Whole
period 1998–2000 2001–2004 2005–2008
Prevalence 15.5 31.3 11.8 7.4
Sensitivity 89.0 90.2 83.3 92.9
Specificity 92.7 95.6 94.8 89.7
Positive Predictive Value 69.2 90.2 68.2 41.9
Negative Predictive Value 97.9 95.6 97.7 99.4
Positive Likelihood Ratio 12.3 20.3 16.0 9.0
Negative Likelihood Ratio 0.1 0.1 0.2 0.1
doi:10.1371/journal.pone.0038729.t003
Table 4. Bayesian probabilities of test parameters used. ADA
$40 U/L and Lymphocytes $50%.
ADA $40 U/L and Lymphocytes $50%
Whole
period 1998–2000 2001–2004 2005–2008
Prevalence 15.5 31.3 11.8 7.4
Sensitivity 86.3 87.8 83.3 85.7
Specificity 98.3 100 99.3 96.6
Positive Predictive Value 90.0 100 93.8 66.7
Negative Predictive Value 97.5 94.7 97.8 98.8
Positive Likelihood Ratio 49.2 - 111.7 25.0
Negative Likelihood Ratio 0.1 0.1 0.2 0.2
doi:10.1371/journal.pone.0038729.t004
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doi:10.1371/journal.pone.0038729.g001
Figure 2. Cases of tuberculosis pleural effusion (TPE) and malignant effusion as a function of age.
doi:10.1371/journal.pone.0038729.g002
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38729In conclusion, local prevalence of TPE has a more limited
impact than expected (by Bayesian interpretation) on the
diagnostic value of ADA when combined with LP, remaining
a useful diagnostic tool in low-to-intermediate prevalence
scenarios. In our experience, ADA $40 U/l is a highly suitable
cut-off level, and in patients younger than 40 years it might
Figure 3. Prevalence of TPE (bars) and incidence rate of tuberculosis (line) in the Bajo Deba Area, Gipuzkoa, Basque Country (1998–
2008).
doi:10.1371/journal.pone.0038729.g003
Figure 4. Pre-test and post-test probabilities. (+) Positive test, (-) Negative test.
doi:10.1371/journal.pone.0038729.g004
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38729constitute a virtual diagnosis of TPE when effusions are
lymphocytic.
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